Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women.

What Was Tested

This randomized controlled trial looks at Estradiol.

As an indirect probe of estrogen-regulated hypothalamic somatostatin restraint, the present study monitors the ability of short-term oral E2 supplementation to modulate GH secretion during combined continuous stimulation by recombinant human GHRH [GHRH-(1-44)-amide] and the potent and selective synthetic GH-releasing peptide, GHRP-2.

According to a simplified tripeptidyl model of GH neuroregulation, the effects of estrogen in this dual secretagogue paradigm should mirror alterations in endogenous somatostatinergic signaling.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, women only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Estradiol study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Estradiol group a baseline to be compared against.

The resultant GH time series was evaluated by deconvolution analysis, the approximate entropy statistic, and cosine regression to quantitate pulsatile, entropic (feedback-sensitive), and 24-h rhythmic GH release, respectively.

What Was Measured

No primary measure of pulsatile or basal GH release was altered by the disparate sex steroid milieu, i.e.

PubMed files the paper under topics including Circadian Rhythm, Entropy, Estradiol, Feedback, Growth Hormone-Releasing Hormone, Hormones and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Estradiol.

The publication is from 2002 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: all human trials.